| Patents for A61P 43 - Drugs for specific purposes, not provided for in groups (156,317) |
|---|
| 01/30/2003 | US20030021840 High dose solid unit oral pharmaceutical dosage form of amorphous nelfinavir mesylate and process for making same |
| 01/30/2003 | US20030021788 Novel human STRA6-like protein and nucleic acids encoding the same |
| 01/30/2003 | US20030021787 In situ therapy; sustained release |
| 01/30/2003 | US20030021786 Treatment and prevention of cancerous and pre-cancerous conditions of the liver, lung and esophagus |
| 01/30/2003 | US20030021785 Use of rank antagonists to treat cancer |
| 01/30/2003 | US20030021776 Regulation of angiogenesis with zinc finger proteins |
| 01/30/2003 | US20030021768 Viral mutants that selectively replicate in targeted human cancer cells |
| 01/30/2003 | US20030021767 Recombinant p53 adenovirus methods and compositions |
| 01/30/2003 | US20030021766 Nucleic acid mucosal immunization |
| 01/30/2003 | US20030021765 Polymer conjugates of interferon beta-1a and uses |
| 01/30/2003 | US20030021755 Headache therapy |
| 01/30/2003 | US20030021754 Aerosols; vaporization, cooling |
| 01/30/2003 | US20030021753 Delivery of antiemetics through an inhalation route |
| 01/30/2003 | CA2454873A1 Novel transformed cell, method for screening anti-aging agent, and anti-aging agent |
| 01/30/2003 | CA2454543A1 2-(aminomethyl)-tetrahydro-9-oxa-1,3-diaza-cyclopenta[a]naphthalenyl derivatives with antipsychotic activity |
| 01/30/2003 | CA2454423A1 Method and reagents for identifying gene targets for treating breast cancer |
| 01/30/2003 | CA2454418A1 Compositions and methods for use of bioactive agents derived from sulfated and sulfonated amino acids |
| 01/30/2003 | CA2454187A1 Compounds useful for treatment or prevention of disease mediated by alpha-2b-adrenoceptor |
| 01/30/2003 | CA2454185A1 Ntb-a, a surface molecule involved in natural killer cells activity |
| 01/30/2003 | CA2454059A1 Substituted piperazine compounds and their use as fatty acid oxidation inhibitors |
| 01/30/2003 | CA2453997A1 Porphyrin derivatives for photodynamic therapy |
| 01/30/2003 | CA2453967A1 Peptides effective in the treatment of tumors and other conditions requiring the removal or destruction of cells |
| 01/30/2003 | CA2453965A1 Peptides effective in the treatment of tumors and other conditions requiring the removal or destruction of cells |
| 01/30/2003 | CA2453860A1 Imidazopyridinones as p38 map kinase inhibitors |
| 01/30/2003 | CA2453613A1 Sulfonyl aryl hydroxamates and their use as matrix metalloprotease inhibitors |
| 01/30/2003 | CA2453602A1 Use of sulfonyl aryl or heteroaryl hydroxamic acids and derivatives thereof as aggrecanase inhibitors |
| 01/30/2003 | CA2453594A1 Acylsemicarbazides as cyclin dependent kinase inhibitors useful as anti-cancer and anti-proliferative agents |
| 01/30/2003 | CA2453478A1 Agent for treatment of cerebral ischemic diseases |
| 01/30/2003 | CA2453294A1 Phenylacetamido-thiazole derivatives, process for their preparation and their use as antitumor agents |
| 01/30/2003 | CA2453108A1 Combinations comprising epothilones and pharmaceutical uses thereof |
| 01/30/2003 | CA2452832A1 .gamma.-secretase in vitro screening assay |
| 01/30/2003 | CA2452678A1 Combination of eplerenone and an hmg coa reductase inhibitor |
| 01/30/2003 | CA2452541A1 (pyridinyl and pyrimidyl) trienoic acid derivatives as retinoid x receptor modulators |
| 01/30/2003 | CA2452322A1 Inhibitors of the ice/ced-3 family of cysteine proteases |
| 01/30/2003 | CA2452009A1 Chemical compounds |
| 01/30/2003 | CA2451530A1 Chemical compounds |
| 01/30/2003 | CA2451445A1 Imidazo-triazine derivatives as ligands for gaba receptors |
| 01/30/2003 | CA2450437A1 1-phenylsulphonyl-1,3-dihydro-2h-indol-2-one derivatives, their preparation and their therapeutic application |
| 01/30/2003 | CA2443524A1 Methods of profiling gene expression, protein or metabolite levels |
| 01/29/2003 | WO2002009713A2 Selective pde 2 inhibitors, used as medicaments for improving cognition |
| 01/29/2003 | EP1279676A1 Porphyrin derivatives for photodynamic therapy |
| 01/29/2003 | EP1279674A2 Acetylenic ortho-sulfonamido and phosphinic acid amido bicyclic heteroaryl hydroxamic acids as TACE inhibitors |
| 01/29/2003 | EP1279666A1 1-diphenylmethyl-pyrazole derivatives as opioid receptor ligands |
| 01/29/2003 | EP1279662A1 Process for preparing phenylcyclohexan-1-ylcarboxylic acids |
| 01/29/2003 | EP1279412A2 Pressure-mediated intracellular delivery of molecules of microparticles |
| 01/29/2003 | EP1279400A1 Modifying the fatty acid composition of cell membranes of organs and tissues |
| 01/29/2003 | EP1279332A2 Transgenic non-human mammal |
| 01/29/2003 | EP1279039A1 Diagnostic assay and method of treatment involving macrophage inhibitory cytokine -1 (mic-1) |
| 01/29/2003 | EP1278859A2 Human protein kinases and protein kinase-like enzymes |
| 01/29/2003 | EP1278846A2 Cytoskeleton-associated proteins |
| 01/29/2003 | EP1278843A2 Rna metabolism proteins |
| 01/29/2003 | EP1278842A2 Dna encoding the prost 03 polypeptide |
| 01/29/2003 | EP1278829A2 Surfactant protein d for the prevention and diagnosis of pulmonary emphysema |
| 01/29/2003 | EP1278826A1 Novel proteins |
| 01/29/2003 | EP1278824A2 Clearance of ras-mediated neoplastic cells from mixed cellular compositions using reovirus |
| 01/29/2003 | EP1278823A2 Clearance of neoplastic cells from mixed cellular compositions using viruses |
| 01/29/2003 | EP1278778A2 Modified peptides, comprising an fc domain, as therapeutic agents |
| 01/29/2003 | EP1278777A2 G protein coupled receptor (gpcr) agonists and antagonists and methods of activating and inhibiting gpcr using the same |
| 01/29/2003 | EP1278776A2 Isolated human transporter proteins, nucleic acids and uses thereof |
| 01/29/2003 | EP1278775A2 Isolated human g-protein coupled receptors that are members of the aminergic subfamily, nucleic acid molecules encoding human gpcr proteins, and uses thereof |
| 01/29/2003 | EP1278774A2 Human g-protein coupled receptors |
| 01/29/2003 | EP1278772A2 Glucagon antagonists |
| 01/29/2003 | EP1278771A2 A method for activating only the vascular endothelial growth factor receptor-3 and uses thereof |
| 01/29/2003 | EP1278767A1 Albumin fusion proteins |
| 01/29/2003 | EP1278763A1 3-nitrogen-6,7-dioxygen steroids and uses related thereto |
| 01/29/2003 | EP1278759A1 Bis-(n,n'-bis-(2-haloethyl)amino) phosphoramidates as antitumor agents |
| 01/29/2003 | EP1278751A1 Tricyclic fused pyridine and pyrimidine derivatives as crf receptor antagonists |
| 01/29/2003 | EP1278750A1 Imidazopyrimidine derivatives and triazolopyrimidine derivatives |
| 01/29/2003 | EP1278749A1 USE OF 5-THIO-, SULFINYL- AND SULFONYLPYRAZOLO 3,4-b]-PYRIDINES AS CYCLIN DEPENDENT KINASE INHIBITORS |
| 01/29/2003 | EP1278748A2 Inhibitors of human phosphatidyl-inositol 3-kinase delta |
| 01/29/2003 | EP1278744A1 Heterobicyclic sulfonamides and their use as platelet adp receptor inhibitors |
| 01/29/2003 | EP1278735A1 2,4-di(hetero-)arylamino(-oxy)-5-substituted pyrimidines as antineoplastic agents |
| 01/29/2003 | EP1278734A2 Method of treatment using phenyl and biaryl derivatives as prostaglandin e inhibitors and compounds useful therefore |
| 01/29/2003 | EP1278732A1 1-aroyl-piperidinyl benzamidines |
| 01/29/2003 | EP1278729A1 Benzosuberonylpiperidine compounds as analgesics |
| 01/29/2003 | EP1278728A1 Pyrrolidine and piperidine derivatives and their use for the treatment of neurodegenerative disorders |
| 01/29/2003 | EP1278723A2 P-(sulfonyl)-aryl and -heteroaryl amines |
| 01/29/2003 | EP1278722A1 Aryl and heteroaryl sulfonates |
| 01/29/2003 | EP1278719A1 Naphthamide neurokinin antagonists for use as medicaments |
| 01/29/2003 | EP1278716A1 Cyclohexylamine derivative as subtype selective nmda receptor antagonists |
| 01/29/2003 | EP1278546A1 Combination therapy of respiratory diseases using antibodies and anti-inflammatory agents |
| 01/29/2003 | EP1278545A1 Combination therapy of respiratory diseases using antibodies |
| 01/29/2003 | EP1278544A2 Albumin fusion proteins |
| 01/29/2003 | EP1278543A2 Antibody binding alpha4beta7 integrin and its use to treat inflammatory bowel disease |
| 01/29/2003 | EP1278532A1 Plant extract of the olea europaea species as no-synthase inhibitor and uses |
| 01/29/2003 | EP1278522A2 Pde-v inhibitors for treatment of parkinson's disease |
| 01/29/2003 | EP1278509A1 Lipochroman-6 as no-synthase inhibitor and uses |
| 01/29/2003 | EP1278508A1 Plant extract of the species i vitis vinifera /i as no-synthase inhibitor and uses |
| 01/29/2003 | EP1278502A2 Protease inhibitors |
| 01/29/2003 | EP1210349B1 PYRAZOLO 4,3-d]PYRIMIDINES |
| 01/29/2003 | EP1119334B1 Two chamber cartridge for atomizers |
| 01/29/2003 | EP1105387B1 Prodrugs of proton pump inhibitors |
| 01/29/2003 | EP1102761B1 Cyclopentabenzofuran derivatives and their use |
| 01/29/2003 | EP1030836B1 Hydroxamic and carboxylic acid derivatives having mmp and tnf inhibitory activity |
| 01/29/2003 | EP1028948B1 Phenyl-alkyl-imidazoles as h3 receptor antagonists |
| 01/29/2003 | EP1024815B1 Pharmaceutical compositions for oral administration of molecular iodine |
| 01/29/2003 | EP0984966B1 9-AZABICYCLO(3.3.1)NON-2-ENE AND NONANE DERIVATIVES AS CHOLINERGIC LIGANDS AT NICOTINIC ACh RECEPTORS |
| 01/29/2003 | EP0889884B1 1,2,4-triazine derivatives for the inhibition of protein glycosylation |
| 01/29/2003 | EP0888319B1 Substituted 1,2,3,4-tetrahydronaphthalene derivatives |
| 01/29/2003 | EP0828483B1 Use of tropolone derivatives as inhibitors of the enzyme inositol monophosphatase |